Efmody (hydrocortisone)
- Region
- 🇪🇺 EU
- Active substance
- hydrocortisone
- Company
- Immedica Pharma AB
- Status
- Authorised
- Therapeutic area
- Adrenal Hyperplasia, Congenital
- CHMP opinion
- Thu 25 Mar 2021
- EU approval
- Thu 27 May 2021
- Application
- EMEA/H/C/005105
- ATC
- H02AB09
- Official record
- www.ema.europa.eu
Indication
Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Alkindi Authorised · Immedica Pharma AB
- 🇪🇺 Hydrocortisone Aguettant Application withdrawn · Laboratoire Aguettant
- 🇪🇺 Plenadren Authorised · Takeda Pharmaceuticals International AG Ireland Branch
Follow Efmody
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.